Breakthrough in Breast Cancer for 2.3 Million Women: evERA Trial Delivers 70% ER Positive Insight with Giredestrant Combo

Roche announced encouraging results from its evERA phase III trial (NCT05306340). The study tested the oral combination therapy of giredestrant with everolimus against standard endocrine therapy with everolimus in people with estrogen receptor (ER) positive, HER2 negative advanced breast cancer. Results showed clear improvement in disease control, including for patients carrying ESR1 mutations, which are known to drive treatment resistance. Side effects stayed consistent with what doctors expected, and the treatment comes as a convenient oral regimen. This development matters because ER positive breast cancer accounts for around 70% of all breast cancer cases worldwide.

2.3 Million Reasons to Hope 

The global impact of breast cancer is staggering. It is the number one cause of cancer related deaths among women and the second most common type of cancer overall. Every year, approximately 2.3 million women are diagnosed with breast cancer, and the disease claims the lives of 670,000 people annually. Here is where Roche’s new non-intravenous treatment can potentially improve outcomes for even a fraction of this population. 

A 70% Step Forward for Breast Cancer Treatment

The evERA trial had two main goals. It measured progression free survival (PFS), which means the length of time patients live without their cancer worsening or dying from any cause. Researchers looked first at the intention to treat the population that included everyone enrolled. Research shows that up to 40% of people with oestrogen receptor positive breast cancer in the post CDK inhibitor setting develop a specific genetic change known as an ESR1 mutation. This mutation is a common mechanism that cancer cells use to resist standard endocrine therapies. When this mutation occurs, the cancer cells can continue to grow despite treatment, making the disease more difficult to manage.

In both groups, the giredestrant and everolimus combination worked better than standard endocrine therapy with everolimus. Patients lived longer without their disease progressing, and the benefit was considered both statistically significant and clinically meaningful. While overall survival (OS) data are still too early to confirm, initial trends show a possible advantage. Roche plans to continue following patients to collect mature OS results.

The trial’s results are particularly notable because they show a statistically significant and clinically relevant benefit in both the overall patient population and within a specific group of patients whose tumors carried a mutation known as ESR1. This represents a major development because it is the first positive head to head Phase III trial for a treatment regimen that uses a selective oestrogen receptor degrader, or SERD, as an all oral therapy. The success of this approach could fundamentally change the way advanced breast cancer is treated, offering a new, non-intravenous option to patients who have exhausted previous standard therapies. In addition to the positive efficacy data, the all oral combination was well tolerated, with a safety profile consistent with the individual treatments. While overall survival data are not yet mature, a positive trend has been observed, with continued follow up underway.

Safety Profile Matches What Doctors Expected

Safety is always a top concern in cancer care. The trial confirmed that giredestrant plus everolimus did not bring unexpected risks. Side effects were consistent, meaning that adding giredestrant to everolimus did not create new safety problems.

Another important point is convenience. Both medicines are fully oral prescriptions. Many breast cancer treatments require injections or frequent hospital visits, which can disrupt daily life. An oral regimen may ease that burden, helping patients stay on treatment while managing their routines with fewer interruptions.

Why evERA Matters in the Bigger Picture

The evERA trial is the first phase III study to test a next generation selective estrogen receptor degrader (SERD). It compared giredestrant head to head with standard therapy when combined with everolimus. The design brought together two strategies. One drug breaks down the estrogen receptor. The other blocks cancer cell growth signals. Results showed this two pronged approach can give patients more time before their cancer worsens. The benefit was seen even in those already resistant to earlier treatments.

This trial may mark an important step forward. Patients with ESR1 mutations often have few options once their disease progresses. An oral therapy that controls cancer for longer while keeping safety in line is meaningful. It matters for both patients and the doctors who treat them.

Roche plans to present the full results at a medical meeting. The company will also share the data with regulators. That could bring this option closer to clinical practice.

Author

[email protected]